open-label BE trials maintain blindness [Study Per­for­mance]

posted by kimhuang – China, 2023-10-18 02:50 (583 d 07:27 ago) – Posting: # 23762
Views: 4,007

❝ So there are no SOP w.r.t. pre-dose concentration, abnormal PK concentration, λz estimation? Generally QA goes ahead with protocol inclusion/exclusion criteria and SOP of BA.


there's no SOP about handing these cases, case-by-case discuss in blinded data review meeting.

❝ Does BA team also have access to CRF? Then how it is blinded?


BA is blinded.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,679 registered users;
304 visitors (0 registered, 304 guests [including 72 identified bots]).
Forum time: 10:17 CEST (Europe/Vienna)

Pharmacokinetics may be simply defined as
what the body does to the drug,
as opposed to pharmacodynamics, which may be defined as
what the drug does to the body.    Leslie Z. Benet

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5